Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL  by Nagel, Daniel et al.
Cancer Cell
ArticlePharmacologic Inhibition of MALT1 Protease
by Phenothiazines as a Therapeutic Approach
for the Treatment of Aggressive ABC-DLBCL
Daniel Nagel,1 Stefani Spranger,3 Michelle Vincendeau,1 Michael Grau,4 Silke Raffegerst,3 Bernhard Kloo,1
Daniela Hlahla,1 Martin Neuenschwander,5 Jens Peter von Kries,5 Kamyar Hadian,2 Bernd Do¨rken,6 Peter Lenz,4
Georg Lenz,6 Dolores J. Schendel,3 and Daniel Krappmann1,*
1Research Unit Cellular Signal Integration
2Assay Development and Screening Platform
Helmholtz Zentrum Mu¨nchen–German Research Center for Environmental Health, Institute of Molecular Toxicology and Pharmacology,
Ingolsta¨dter Landstrasse. 1, 85764 Neuherberg, Germany
3Helmholtz Zentrum Mu¨nchen–German Research Center for Environmental Health, Institute of Molecular Immunology and Immune
Monitoring Platform, Marchioninistrasse 25, 81377 Munich, Germany
4Department of Physics, Philipps-University Marburg, Renthof 5, 35032 Marburg, Germany
5Leibniz-Institut fu¨r Molekulare Pharmakologie, Robert-Roessle-Strasse 10, 13125 Berlin, Germany
6Department of Hematology, Oncology and Tumorimmunology, Molecular Cancer Research Center, Charite´–University Medicine Berlin,
Augustenburger Platz 1, Forum 4, 13353 Berlin, Germany
*Correspondence: daniel.krappmann@helmholtz-muenchen.de
http://dx.doi.org/10.1016/j.ccr.2012.11.002SUMMARYProteolytic activity of the mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1)
paracaspase is required for survival of the activated B cell subtype of diffuse large B cell lymphoma (ABC-
DLBCL). We have identified distinct derivatives of medicinal active phenothiazines, namely mepazine,
thioridazine, and promazine, as small molecule inhibitors of the MALT1 protease. These phenothiazines
selectively inhibit cleavage activity of recombinant and cellular MALT1 by a noncompetitive mechanism.
Consequently, the compounds inhibit anti-apoptotic NF-kB signaling and elicit toxic effects selectively on
MALT1-dependent ABC-DLBCL cells in vitro and in vivo. Our data provide a conceptual proof for a clinical
application of distinct phenothiazines in the treatment of ABC-DLBCL.INTRODUCTION
Upon antigenic stimulation, mucosa-associated lymphoid tissue
lymphoma translocation protein-1 (MALT1) is a key mediator of
upstream NF-kB signaling to control lymphocyte activation,
survival, and differentiation (Hailfinger et al., 2009a; Thome,
2008). Together with CARMA1 (also known as CARD11) and
BCL10, MALT1 assembles the CBM complex that bridges prox-
imal antigen receptor signaling events to the IkB kinase (IKK)
complex, the gatekeeper of the canonical NF-kB pathway
(Scheidereit, 2006). Upon T cell antigen receptor (TCR)/CD28Significance
Cleavage activity of the mucosa-associated lymphoid tissue
contributes to the oncogenic potential of MALT1 in MALT lym
most aggressive lymphoma entities. We identified small mole
as potent and selective inhibitors of the MALT1 protease. MAL
in vitro and in vivo, revealing their potency in achieving target-
thiazines have been widely used as antipsychotic drugs even in
well-defined toxicity, pharmacokinetics, and pharmacodynam
compounds in ABC-DLBCL therapy.
Cancostimulation, MALT1 acts as a protein scaffold that recruits
other critical signaling molecules like TRAF6, caspase 8, and
A20 to the CBM complex (Thome, 2008). Furthermore, covalent
ubiquitin modifications in MALT1 catalyzed by the E3 ligase
TRAF6 facilitate the association of two downstream protein
kinase complexes, TAB2-TAK1 and NEMO-IKKa/b, which ulti-
mately leads to IKK activation (Oeckinghaus et al., 2007).
In addition to its scaffolding function, MALT1 contains a
paracaspase domain that displays high homology to caspases
from mammals and metacaspases from plants and fungi (Uren
et al., 2000). Like metacaspases, MALT1 cleaves substrateslymphoma translocation protein-1 (MALT1) paracaspase
phoma and ABC-DLBCL, the latter representing one of the
cular compounds belonging to the class of phenothiazines
T1 inhibition by phenothiazines selectively kills ABC-DLBCL
directed treatment of MALT1-dependent lymphoma. Pheno-
long-term treatment of schizophrenia and psychosis. Thus,
ics can facilitate clinical trials for an off-label use of these
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MALT1 Inhibition by Phenothiazines in DLBCLafter arginine residues, indicating that the enzymatic cleavage
activity is quite distinct from caspases, which in general require
an aspartate at the P1 position (Vercammen et al., 2004). MALT1
proteolytic activity is induced upon TCR/CD28 costimulation,
which promotes cleavage of the substrates BCL10, A20,
CYLD, and RelB (Coornaert et al., 2008; Hailfinger et al., 2011;
Rebeaud et al., 2008; Staal et al., 2011). Inhibition of MALT1
protease activity by the antagonistic tetrapeptide Z-VRPR-
FMK, which was originally designed as an inhibitor of metacas-
pases in plants, impairs optimal NF-kB activation and inter-
leukin-2 (IL-2) production in T cells (Du¨wel et al., 2009; Rebeaud
et al., 2008). Similarly, mutation of the catalytic cysteine 464
renders MALT1 proteolytically inactive and also impairs IL-2
production after complementation of MALT1-deficient T cells
(Du¨wel et al., 2009). These results indicate that small molecule
inhibitors that selectively target MALT1 protease activity may
be promising candidates for clinical use in T cell-dependent im-
mune diseases, such as allergic inflammation or autoimmunity.
A tumor-promoting role of MALT1 has been found in a subset
of diffuse large B cell lymphoma (DLBCL) and MALT lymphoma
(Ngo et al., 2006). By gene expression profiling, DLBCL can be
classified into distinct entities and the most abundant subtypes
are the ABC-DLBCL and the germinal center B cell-like (GCB-)
DLBCL (Alizadeh et al., 2000; Rosenwald and Staudt, 2003;
Rosenwald et al., 2002; Savage et al., 2003; Wright et al.,
2003). Based on the gene expression signature, the ABC-DLBCL
subtype originates from B lymphocytes stimulated through
their B cell antigen receptor (BCR). With a 5-year survival rate
of 35%, patients with ABC-DLBCL have the worst prognosis,
reflecting the aggressive clinical behavior of ABC-DLBCL cells
(Lenz et al., 2008b). The hallmark of ABC-DLBCL, but not
GCB-DLBCL, cells is the constitutive activation of the NF-kB
signaling pathway (Alizadeh et al., 2000; Davis et al., 2001).
Congruent with this, a recent genetic study of the DLBCL re-
vealed the preferential association of gene alterations in the
NF-kB and BCL6-BLIMP1 axis in ABC-DLBCL and in BCL2
and MYC in GCB-DLBCL, suggesting that anti-apoptotic NF-
kB signaling is indeed critical for ABC-DLBCL survival (Pasqua-
lucci et al., 2011). While some ABC-DLBCL patients carry onco-
genic CARMA1 mutations (Lenz et al., 2008a), the majority of
ABC-DLBCL is characterized by chronic active BCR signaling
and in 20% of the cases activating mutations in the BCR prox-
imal regulator CD79A and CD79B are found (Davis et al., 2010).
Consistent with a requirement for BCR signaling, an RNA inter-
ference screen identified CARMA1, BCL10, or MALT1 as critical
regulators of NF-kB activation, and survival and growth of ABC-
DLBCL (Ngo et al., 2006). Furthermore, inhibition of MALT1
proteolytic activity by Z-VRPR-FMK inhibits NF-kB-dependent
gene expression and exerts toxic effects specifically in ABC-
DLBCL cells (Ferch et al., 2009; Hailfinger et al., 2009b).
MALT1 paracaspase activity also contributes to the pathogen-
esis of MALT lymphoma that is characterized by the transloca-
tion t(11;18)(q21;q21), which creates a fusion between the C
terminus of MALT1, including the paracaspase domain, and
the N terminus of IAP2 (API2-MALT1) (Isaacson and Du, 2004).
The paracaspase domain of API2-MALT1 fusion protein cata-
lyzes the cleavage of NIK and thereby enhances noncanonical
NF-kB activation, which confers apoptosis resistance (Rose-
beck et al., 2011). Thus, specific small molecule inhibitors826 Cancer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Incagainst theMALT1 paracaspase could be beneficial for the treat-
ment of lymphoma associated with deregulated MALT1 activity,
such as ABC-DLBCL and MALT lymphoma.
The peptide Z-VRPR-FMK provided an initial hint that MALT1
inhibition is a feasible strategy for interfering with survival of
ABC-DLBCL cells in vitro. However, due to poor pharmacologic
properties, Z-VRPR-FMK needs to be administered in very
high concentrations to exert effects on cells and antagonistic
peptides in general are not adequate for clinical applications.
The goal of this study was to identify small molecule inhibitors
for pharmacologic inhibition of theMALT1 protease and to deter-
mine the effects of theseMALT1 inhibitors on ABC-DLBCL prolif-
eration and survival in vitro and in vivo.
RESULTS
Identification of Phenothiazine Derivatives as Selective
MALT1 Protease Inhibitors
To identify small molecular weight compounds that could inhibit
MALT1 protease activity, we purified recombinant GSTMALT1
from Escherichia coli to establish an in vitro protease cleavage
assay suitable for high throughput screening (HTS). GSTMALT1
was incubated for 1 hr at 30C in the presence of 50 mM of the
tetrapeptide substrate Ac-LRSR-AMC, which is derived from
the MALT1 cleavage site in the C terminus of BCL10 (Rebeaud
et al., 2008). Proteolytic activity was determined by measuring
the increase of fluorescence that is emitted after cleavage and
the accompanying release of the fluorophore AMC (Figures 1A
and 1B). MALT1-catalyzed cleavage of Ac-LRSR-AMC is evident
from a robust increase in fluorescence intensity over time. As ex-
pected, mutation of the conserved cysteine (C453A) in the para-
caspase domain of MALT1 (Isoform B) completely abolished
MALT1 catalytic activity (Figure 1B). As expected, the tetrapep-
tide Z-VRPR-FMKblockedMALT1 cleavage activity at low nano-
molar concentrations (Figure 1B; Figure S1A available online). In
contrast, the potent caspase inhibitory peptide Ac-DEVD-CHO
effectively blocked caspase 8 activity at picomolar concentra-
tions, but only marginally reduced MALT1 activity when used
at concentrations up to 200 mM (Figures S1B–S1D).
We screened approx. 18,000 compounds of the ChemBioNet
collection (Lisurek et al., 2010) using the assay format depicted in
Table S1. The primary screen was conducted by measuring the
increase in AMC fluorescence in a 384 half-well format over an
assay time of 20min in the presence of 10 mMof each compound
(see Supplemental Experimental Procedures). Dose-response
assays were performed for secondary hit validation and selec-
tivity on MALT1 was determined by comparing the influence on
caspase 8 activity. These analyses yielded 15 hits, correspond-
ing to 0.08% of the primary screen. When examining the
structure of the 15 hits, we noticed that three of themost efficient
and selective compounds (Figure S1E, compounds A, B, and C)
are derivatives of the tricyclic phenothiazine that contains two
outer benzene rings linked by nitrogen and sulfur atoms in the
inner ring. Also the heterocyclic core found in compound D
displays high structural similarities to phenothiazine, whereby
the nitrogen is replaced by carbon. These initial results sug-
gested that certain phenothiazine derivatives (PD) may act as
MALT1 inhibitors. Moreover, at 50 mM, all four compounds
were reducing MALT1 protease activity to less than 10%, but.
Figure 1. Selective MALT1 Inhibition by Mepazine, Thioridazine, and Promazine
(A) A schematic representation of the MALT1 protease assay for HTS. Cleavage of the fluorophore AMC by GSTMALT1 from the fluorogenic substrate Ac-LRSR-
AMC results in an increase of fluorescence.
(B) Purified recombinant GSTMALT1 from bacterial expression was incubated for 1 hr at 30C with 50 mM of Ac-LRSR-AMC and the proteolytic activity was
determined by measuring the increase of AMC fluorescence. Graph shows a representative of at least five independent experiments.
(C) Chemical structures of the three inhibitory compounds.
(D) Dose-response curves and IC50 values for mepazine, thioridazine, and promazine.
(E) Michaelis-Menten kinetics was determined by increasing the concentration of Ac-LRSR-AMC substrate in the absence or presence of 1 mM mepazine.
(F) GSTMALT1 coupled to glutathione sepharose beads was treated with mepazine (10, 20, or 50 mM) for 30 min. MALT1 activity was assayed after washing the
beads for 0, 3, or 6 times before cleavage reaction was started (mean ± SD; n = 3).
(G) Cleavage of human recombinant caspase 3 and caspase 8 against Ac-DEVD-AMC as substrate (mean ± SD; n = 3).
See also Figure S1 and Table S1.
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itor concentration, indicating that the four PD display a high
selectively for MALT1 (Figure S1F). We also tested the core
phenothiazine scaffold and found that it inhibited MALT1 activity
in a dose-dependent manner (Figure S1G). Notably, our initial
results implied that only the modifications of compound A
seemed to significantly improve the inhibitory potential of the
phenothiazine backbone towardMALT1, suggesting that distinct
phenothiazines could be promising candidates as selective
MALT1 inhibitors.CanMepazine, Thioridazine, and Promazine Act as Potent
and Selective MALT1 Paracaspase Inhibitors
Weobtained 26 commercially available PD, to test their inhibitory
potential (Figure S1H). Whereas most compounds (12–26)
had no or only very weak inhibitory potential (IC50 > 20 mM),
eight compounds (4–11) inhibited MALT1 activity with an IC50
roughly between 5 and 20 mM. Only three PD had an IC50
below 5 mM. Thus, only a small subset of PD was capable
of efficiently inhibiting MALT1. The three most potent com-
pounds represent promazine, thioridazine, and mepazine, thecer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Inc. 827
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MALT1 Inhibition by Phenothiazines in DLBCLlatter initially identified in the screening (Figure 1C). To define the
inhibitory potential, we determined exact IC50 values for each
compound on recombinant full length (FL) GSTMALT1 and an
enzymatically active MALT1 fragment encompassing amino
acids 325 to 760 that contained the paracaspase and C-terminal
Ig-like (Ig3) domains (Figure 1D). Mepazine was most effective in
inhibiting GSTMALT1 FL and GSTMALT1 325-760 with IC50
values of 0.83 and 0.42 mM, respectively. Also thioridazine and
promazine showed a dose-dependent inhibition of GSTMALT1
FL and GSTMALT1 325-760, but the IC50 values were approxi-
mately 4-fold (GSTMALT1 FL) or 8-fold (GSTMALT1 325-760)
higher when compared to mepazine. In contrast, promethazine
(compound 18 in Figure S1H), a drug still being used in the treat-
ment of certain psychiatric disorders and highly related to the
three active PD, did not cause any significant MALT1 inhibition
at concentrations up to 20 mM. These results indicate a high
degree of specificity in MALT inhibition even within the group
of PD.
To test the mode of action, we determined the effect of mepa-
zine in Michaelis-Menten kinetics on the basis of the fluorogenic
MALT1 cleavage assay (Figure 1E). GSTMALT1 FL displayed
a VMAX of 170 RFU/min and the Michaelis-Menten constant
(KM) was calculated to 48 mM, which is in the range of what
has been determined previously (Hachmann et al., 2012). Addi-
tion of mepazine at a concentration around the IC50 (1 mM)
strongly decreased the VMAX to 58 RFU/min while the KM of
48 mM was not altered. Mepazine and other phenothiazines do
not contain reactive groups. However, to confirm that mepazine
acts as a noncovalent reversible inhibitor, we performed wash-
out experiments using GSTMALT1 attached to glutathione se-
pharose beads (Figure 1F). Again, mepazine inhibited MALT1
cleavage activity, but several cycles of washing the GSTMALT1
beads resulted in complete loss of inhibition even at the highest
concentration of the compound (50 mM). Thus, the effects of me-
pazine on MALT1 enzymatic activity revealed a noncompetitive
and reversible mode of MALT1 inhibition by phenothiazines.
Next we assayed the effects of PD on caspases, which are
structurally the closest relatives of MALT1 in mammals (Uren
et al., 2000). Importantly, all three PD did not significantly inhibit
caspase 3 or caspase 8 activity, even at concentrations up to
50 mM (Figure 1G), reflecting the selectivity of the compounds
as MALT1 inhibitors.
Phenothiazines Inhibit MALT1 Activity and IL-2
Induction in T Cells
As MALT1 protease activity is required for T cell responses, we
determined the effects of PD onMALT1 activity and IL-2 produc-
tion in T cells. We performed a MALT1 cleavage assay after
immunoprecipitation (IP) of the protein from Jurkat T cells. Cells
were left untreated or incubated for 3 hr with 10 mM of mepazine
or thioridazine and subsequently left unstimulated or stimulated
with anti-CD3/CD28. MALT1 protease activity was almost unde-
tectable in the absence of stimulation and peaked at 30–60 min
after CD3/CD28 treatment. Addition of either mepazine or thio-
ridazine resulted in a strong reduction ofMALT1 protease activity
in stimulated Jurkat T cells at all time points (Figure 2A). Mepa-
zine and thioridazine incubation also caused a severe reduction
in PMA/Ionomycin (P/I)-stimulated MALT1 protease activity in
Jurkat T cells (Figure S2A). To confirm that both phenothiazines828 Cancer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Incwere inhibiting MALT1 activity inside the cells, we monitored
MALT1 cleavage of RelB after stimulation of Jurkat T cells
(Figure 2B). RelB cleavage product RelBD could be detected
when Jurkat T cells were incubated with proteasome inhibitor
MG132 prior to P/I stimulation to prevent degradation of the
unstable RelB truncation (Hailfinger et al., 2011). As evident
from decreased RelBD levels and a parallel increased expres-
sion of full-length RelB, mepazine and thioridazine impaired
RelB cleavage in a dose-dependent manner (Figure 2B). Similar
to the situation with recombinant MALT1, mepazine was more
efficient in inhibiting cellular MALT1 cleavage activity and signif-
icantly reduced the appearance of RelBD between 2 and 5 mM,
whereas thioridazine was effective above 5 mM.
To determine the impact of MALT1 inhibition by PD on T cell
activation, we measured secreted IL-2 amounts by ELISA after
P/I or anti-CD3/CD28 stimulation of Jurkat T cells in the presence
or absence of mepazine or thioridazine. Both compounds led to
a decrease of IL-2 levels in the media of PD-treated cells after
T cell activation (Figure 2C). To verify that the inhibitory potential
of PD was also detectable in primary T cells, we isolated and
purified murine CD4- positive Th1 T cells and measured IL-2
mRNA induction by qPCR and IL-2 protein levels by ELISA after
anti-CD3/CD28 coligation in the presence or absence of 5 and
10 mM of mepazine or thioridazine (Figures 2D and S2B). Both
IL-2 mRNA induction and protein expression were reduced in
a dose-dependent manner. Finally, we used primary human
peripheral blood mononuclear cells (PBMCs) from three donors
to evaluate whether inhibition of MALT1 activity also promoted
a decreased IL-2 production in primary human T cells (Figure 2E).
Congruent with the previous results, mepazine and thioridazine
treatment led to a significant decrease of IL-2 secretion in
PBMCs of all three donors.
Phenothiazines Inhibit MALT1 Activity and Induction of
NF-kB Target Genes in ABC-DLBCL Cells
Coinciding with a constitutive cleavage of MALT1 substrates, we
previously showed enhancedMALT1 protease activity as a char-
acteristic feature of all ABC-DLBCL cells (Kloo et al., 2011).
To determine the effect of phenothiazines on cellular MALT1
activity, ABC-DLBCL cells were treated for 4 hr with 5 or 10 mM
of mepazine, thioridazine, and promazine. We performed an
anti-MALT1 IP and MALT1 protease activity was determined by
adding the substrate AC-LRSR-AMC to the precipitates. All three
PD inhibited MALT1 protease activity from ABC-DLBCL cells in
a dose-dependent manner (Figure 3A). The inhibition after partial
MALT1 IP purification suggested that binding of PD promotes
MALT1 to adopt an inactive conformation inside the cells. Even
though inhibition of cellular MALT1 activity varied depending on
the individual cell lines and the compounds, in general, mepazine
had the strongest effects and MALT1 activity was reduced by
at least 75% in all ABC-DLBCL cells at 10 mM. Treatment of thio-
ridazine and promazine significantly inhibited cellular MALT1
activity and in agreement with in vitro IC50 data the effects of
both inhibitors were in general weaker compared to mepazine.
Next, we askedwhetherMALT1 inhibition by the two strongest
compounds, mepazine and thioridazine, would also prevent
MALT1 substrate cleavage in ABC-DLBCL cells. RelB was
shown to counteract anti-apoptotic activity of the NF-kB factors
RelA and c-Rel and its cleavage to RelBD by MALT1 releases.
Figure 2. Mepazine and Thioridazine Impair
MALT1-Mediated T Cell Activation
(A) Jurkat T cells were untreated or incubated for
3 hr with 10 mM of mepazine or thioridazine and
then treated with anti-CD3/CD28 as indicated.
Proteolytic activity after immunoprecipitation of
MALT1 was determined by fluorogenic protease
assay (mean ± SD; n = 3).
(B) Jurkat T cells were treated with solvent, me-
pazine, or thioridazine for 3 hr prior to 1 hr MG132
incubation. Afterward, cells were stimulated with
P/I for 30 min. RelB and RelBD were analyzed by
western blot. Blots show a representative of at
least three independent experiments.
(C) IL-2 secretion wasmeasured by ELISA after P/I
or anti-CD3/CD28 stimulation of Jurkat T cells for
20 hr in the presence or absence of mepazine or
thioridazine (mean ± SD; n = 3).
(D) Primary murine CD4+ T cells were treated with
mepazine or thioridazine and stimulated with anti-
CD3/CD28 antibodies for 20 hr and then analyzed
for IL-2 secretion (mean ± SD; n = 3).
(E) Primary human PBMCs from three donors were
treated with mepazine and thioridazine for 3 hr
before induction with anti-CD3/CD28 for 20 hr.
Extracellular IL-2 levels were measured by ELISA
(mean ± SD; n = 3).
See also Figure S2.
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2011). The inherently unstable RelB cleavage product (RelBD)
was detected in ABC-DLBCL cells HBL1, OCI-Ly3, and TMD8
after addition of the proteasome inhibitor MG132 (Figure 3B).
When the cells were treated for 4 hr with 2, 5, or 10 mM of mepa-
zine or thioridazine, the appearance of RelBD cleavage product
was inhibited and full-length RelB was stabilized in a dose-
dependent manner. Correlating with the previous results on re-
combinant and cellular MALT1 inhibition, mepazine was more
effective than thioridazine in inhibiting RelB cleavage. These
results provided clear evidence that mepazine and thioridazine
were effectively inhibiting constitutive cellular MALT1 cleavage
activity in ABC-DLBCL cells.
In the ABC-DLBCL cell line HBL1, a MALT1 expression signa-
ture was generated using the covalently attached antagonistic
tetrapeptide inhibitor Z-VRPR-FMK (Hailfinger et al., 2009b).
To gain insight into whether PD exerted similar cellular effects,
we determined gene expression profiles in HBL1 cells after
different incubation times with mepazine, which most strongly
inhibited MALT1 in previous assays (Figure 3C). When we
compared the expression signature after administration of me-
pazine to the expression profile after Z-VRPR-FMK incubation,
we observed a significant overlap in the genes that are downre-
gulated in response to both treatments. In fact both the antago-
nistic tetrapeptide and the pharmacologic compound mepazineCancer Cell 22, 825–837, Dinhibited many genes quite rapidly and
showed significant effects already after
6 hr of incubation, which further indicated
that both inhibitors were exerting these
cellular effects by acting through MALT1
inhibition. The weaker effects noted with
mepazine after 12 and 24 hr are mostlikely due to the fact that, in contrast to Z-VRPR-FMK, the PD
is inhibiting MALT1 in a noncovalent and reversible manner. As
expected, we also observed differences in the two expression
profiles, which were most likely related to MALT1-independent
off-target effects of either Z-VRPR-FMK or mepazine.
Because MALT1 activity was shown to contribute to NF-kB
activation and target gene expression in ABC-DLBCL cells
(Ferch et al., 2009; Hailfinger et al., 2009a), we also determined
if mepazine treatment impaired NF-kB target gene expression
in HBL1 cells (Figure 4A). For this analysis, we compared relative
changes in the gene expression after increasing times of treat-
ment with mepazine in HBL1 cells by genome-wide expression
arrays to an NF-kB expression signature generated after incuba-
tion with the highly specific IKKb inhibitor MLN120B (Kloo et al.,
2011). Mepazine significantly decreased the overall expression
as well as the proportion of NF-kB target genes in the signature,
clearly indicating that MALT1 inhibition by mepazine, just like
Z-VRPR-FMK, suppressed activation of the NF-kB pathway in
ABC-DLBCL cells.
To verify the effects of mepazine in other ABC-DLBCL cells,
wemonitored protein expression of selected NF-kB target genes
that are known to possess critical functions for ABC-DLBCL
biology (Figures 4B and 4C). One-time mepazine treatment led
to a dose-dependent decrease of anti-apoptotic BCL-XL and
FLIP-L proteins (Figure 4B). Furthermore, ABC- or GCB-DLBCLecember 11, 2012 ª2012 Elsevier Inc. 829
Figure 3. PD Treatment Impairs MALT1 Activity in ABC-DLBCL Cells
(A) Cellular MALT1 activity in ABC-DLBCL was analyzed after 4 hr incubation with mepazine, thioridazine, or promazine (mean ± SD; n = 3).
(B) Cells were treated with solvent, mepazine, or thioridazine for 4 hr prior to 1 hr MG132 incubation. RelB and RelBDwere analyzed via western blot. Blots show
a representative of at least three independent experiments.
(C) Gene expression profiling of the ABC-DLBCL cell line HBL1 after treatment with peptide Z-VRPR-FMK or mepazine (20 mM) for 6, 12, and 24 hr. Gene
expression changes were assessed by DNA microarrays and are depicted according to the color scale shown. A gene was selected as dependent on MALT1
activity if Z-VRPR-FMKdecreased gene expression by at least 33%after all three inhibition time points. This gene expression signaturewas subsequently applied
to expression data following treatment with mepazine. Error bars depict standard error of the mean. Statistical significance of the decrease in the MALT1
signature average in each treated sample was verified by paired t test.
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the NF-kB-regulated cytokines IL-6 and IL-10 was determined
by ELISA (Figure 4C). Whereas GCB-DLBCL cells expressed
low amounts of IL-6 or IL-10, ABC-DLBCL cells secreted both
cytokines albeit to variable extents, reflecting heterogeneity
among the different cell lines.Mepazine did not affect expression
of IL-6 and IL-10 in GCB-DLBCL cells.
Selective Toxicity and Induction of Apoptosis by
Phenothiazines in ABC-DLBCL Cells
Because the three PD efficiently inhibited MALT1 protease
activity in vitro and in vivo, we tested their effect on the viability
of ABC-DLBCL cells. As a control we used three GCB-DLBCL
cell lines, BJAB, Su-DHL-6, and Su-DHL-4 that were previously
shown to be independent of MALT1 proteolytic activity for their830 Cancer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Incgrowth and survival (Ferch et al., 2009). We measured cytotoxic
effects by MTT assays after 2 days of incubation after one-time
compound treatment using increasing concentrations of mepa-
zine, thioridazine, and promazine (Figure 5A). All compounds
caused a decrease of cell viability in the ABC-DLBCL cells
HBL1, OCI-Ly3, U2932, and TMD8, without significantly affect-
ing GCB-DLBCL cells. Furthermore, we determined cell viability
by cell counting after 4 days of incubation in response to a
singular compound treatment (Figure 5B). Congruent with the
MTT assay, the PD also decreased the overall number of viable
ABC-DLBCL cells. Again, the reduced viability was much
more pronounced in ABC-DLBCL cells, while GCB-DLBCL cell
viability was only slightly impaired at the highest concentration
of the compounds. Consistent with the results obtained in the
cellular MALT1 cleavage assay, in general promazine had the.
Figure 4. Mepazine Treatment Impairs NF-kB Target Gene Expression in ABC-DLBCL Cells
(A) Gene expression profiling of the ABC-DLBCL cell line HBL1 after treatment with mepazine (see Figure 3) was compared to the NF-kB gene signature
generated after administration of the specific IKKb inhibitor MLN120B. The significance of the decrease in the NF-kB signature average in each treated sample
was verified by paired t test.
(B) Expression of NF-kB target genes BCL-XL and FLIP-L in ABC-DLBCL cells after mepazine treatment. Protein amounts were examined after 20 hr of treatment
using the indicated concentrations by western blot. Data show a representative of three independent experiments.
(C) ABC- and GCB-DLBCL cells were treated with mepazine for 20 hr and the levels of secreted IL-6 and IL-10 were analyzed via ELISA (mean ± SD; n = 3).
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date that the decrease in viability of ABC-DLBCL cells is linked
to the administration of distinct PD that act as MALT1 inhibitors,
we treated DLBCL cells with promethazine (Figure S3A). Despite
its close structural relation to promazine, promethazine did not
inhibit MALT1 protease activity at concentrations up to 20 mM
(see compound 18 in Figure S1H). Indeed, promethazine did
not significantly inhibit viability of ABC- or GCB-DLBCL cells
after 4 days of treatment, providing further evidence that the
cellular effects of mepazine, thioridazine, and promazine were
dependent on their ability to inhibit MALT1.
To demonstrate that decreased viability of ABC-DLBCL cells
after PD treatment is linked to MALT1-dependent NF-kB inhibi-
tion, we infected HBL1 cells with a lentivirus expressing the
constitutively active mutant IKKb SS176/180EE (caIKKb) and
simultaneously GFP (Figure 5C). GFP-expressing cells were
sorted by FACS, yielding caIKKb or mock-infected populations
of more than 95% GFP-positive cells. caIKKb expression was
verified by western blotting (Figure S3B). As expected, the
viability of mock-infected HBL1 cells was strongly reduced in
response to increasing doses of mepazine or thioridazine. In
contrast, caIKKbexpressing cells were resistant to the incuba-
tion of the PD. Thus, augmented IKKb signaling counteracts the
toxicity of PD, providing further evidence that PD are acting
upstream of IKKb through MALT1 inhibition.CanFor efficient anticancer drugs it is required that they exert toxic
effects by enhancing cell death to eradicate the tumor cells.
Therefore, we determinedwhethermepazine, as themost potent
MALT1 inhibitor, affected viability of ABC-DLBCL cells by en-
hancing apoptosis (Figure 5D). To this end, DLBCL cells were
treated for 5 days with 15 mM mepazine and apoptotic cells
were identified by FACS as AnnexinV-PE positive and 7-AAD-
negative cells. Mepazine provoked an enhanced apoptotic rate
in all ABC-DLBCL cells, while apoptosis was not increased in
the two GCB-DLBCL control cells. Thus, PD are selectively toxic
to ABC-DLBCL cells and toxicity is at least partially due to
enhanced apoptosis in the affected lymphoma cells, revealing
a potential use of mepazine and structurally related compounds
for ABC-DLBCL therapy.
Mepazine and Thioridazine Impede Growth of ABC-
DLBCL In Vivo
We determined whether mepazine and thioridazine could also
exert effects on lymphoma growth in vivo in a murine DLBCL
xenogeneic tumor model. For this purpose, the ABC-DLBCL
cell line OCI-Ly10 and the GCB-DLBCL cell line Su-DHL-6
were injected as subcutaneous xenografts into NOD/scid IL-
2Rgnull (NSG) mice (Figure 6A). Both tumor cell lines were en-
grafted simultaneously on opposite flanks of individual mice.
Starting 1 day after injection, the mice were treated bycer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Inc. 831
Figure 5. PD Are Selectively Toxic to ABC-DLBCL Cells
(A) ABC-DLBCL cell lines (HBL1, OCI-Ly3, U2932, TMD8) and GCB-DLBCL cell lines (BJAB, Su-DHL-6, Su-DHL-4) were treated with indicated concentrations of
mepazine, thioridazine, or promazine (single treatment) for 2 days and their viability was subsequently analyzed with a MTT cytotoxicity test (mean ± SD; n = 3).
(B) Viability of cells treatedwithmepazine, thioridazine, or promazine (single dose treatment) for 4 days was determined by trypan blue exclusion counting of living
cells. Data represent the mean of three independent experiments.
(C) HBL1 cells were lentivirally transduced to co-express caIKKb along with GFP or GFP alone (mock). GFP-positive cells were sorted via FACS and treated at
day 0with the indicated concentrations ofmepazine or thioridazine. Cells were treated for 4 days and viable cells were counted by trypan blue exclusion every day
during the treatment. Values represent the relative cell numbers compared to the untreated controls (mean ± SD; n = 3).
(D) ABC-DLBCL and GCB-DLBCL cell lines were treated for 5 days with 15 mM mepazine. Apoptotic cells were identified by FACS analysis as AnnexinV-PE
positive and 7-AAD negative cells (mean ± SD; n = 3).
See also Figure S3.
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MALT1 Inhibition by Phenothiazines in DLBCLintraperitoneal (i.p.) administration of solvent or either mepazine
(16 mg/kg) or thioridazine (12 mg/kg). In control-treated mice,
massive tumors grew from both DLBCL cell lines within 3 weeks832 Cancer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Incof transplantation. Daily administration of mepazine or thiorida-
zine strongly impaired the expansion of the ABC-DLBCL cell
line OCI-Ly10. In contrast, both PD completely failed to exert.
Cancer Cell
MALT1 Inhibition by Phenothiazines in DLBCLany inhibitory effects on the progression of the GCB-DLBCL cell
line Su-DHL-6 in the same animals. To ascertain that mepazine
and thioridazine are not only impeding growth in the initiation
phase of xenografted OCI-Ly10 cells, but are also affecting
grown tumors, we allowed OCI-Ly10 and Su-DHL-6 xenografted
tumors to grow to 75 mm2 before treatment (Figure 6B). Again,
mepazine and thioridazine strongly reduced the progression
of OCI-Ly10 tumors while having no effect on the growth of
Su-DHL-6 tumors in this setting. Thus, PD are in fact able to
inhibit growth of a preformed ABC-DLBCL tumor.
Thioridazine is orally available in humans and pharmacokinetic
(PK) studies led to a consensus therapeutic range between
200 and 2000 ng/ml in the blood of patients (Baumann et al.,
2004). To determine if the concentrations of thioridazine in the
blood of NSGmice after i.p. injection are not exceeding this ther-
apeutic window, we measured serum concentrations in NSG
mice after 0, 1, 2, 6, and 24 hr in response to acute dosing of
12 mg/kg thioridazine. Thioridazine concentrations between
170 and 270 ng/ml were measured 1 hr after dosing and the
levels rapidly decreased thereafter (Figure 6C). After 24 hr, thio-
ridazine levels were below the detection limit (20 ng/ml).
To show that mepazine and thioridazine were acting directly
on the tumor cells, we determined the induction of apoptosis
in the tumor tissue. Transplanted tumors were removed at the
end of the treatment period (21 days; see Figure 6A) and
apoptotic cells were visualized by TUNEL staining on sections
of the tumor tissue (Figure 6D). Congruent with the selective
in vivo toxicity, mepazine or thioridazine treatment increased
the number of apoptotic cells in the xenografted ABC-DLBCL
cell line OCI-Ly10, while no induction of apoptosis was observed
in the in GCB-DLBCL cell line Su-DHL-6. Furthermore, con-
stitutive cleavage of the MALT1 substrate RelB was impaired
after mepazine and thioridazine treatment in specimens of xen-
ografted OCI-Ly10 tumors, revealing that also in mice the
compounds were indeed acting by inhibiting MALT1 activity in
the tumor cells (Figure 6E). Thus, the murine tumor model
provided evidence that MALT1 inhibition by phenothiazines
selectively kills MALT1-dependent DLBCL in vivo and indicates
a potential therapeutic benefit for use of the known compounds
in ABC-DLBCL therapy.
DISCUSSION
In this study, we have identified PD as small molecule inhibi-
tors that effectively and selectively inhibit proteolytic activity of
recombinant and cellular MALT1. Importantly, only a distinct
subset of PD inhibited MALT1, with the best inhibitory activity
found for mepazine, thioridazine, and promazine, three known
organic compounds that have been in clinical use as anti-
psychotic or sedative drugs. All three PD interfered with
inducible MALT1 activity in activated T cells and constitutive
activity in ABC-DLBCL cells. Furthermore, mepazine and thiorid-
azine caused impaired T cell activation as well as reduced
viability that was selective for the ABC subtype of DLBCL,
processes that were shown to be critically dependent on
MALT1 activity (Du¨wel et al., 2009; Ferch et al., 2009; Hailfinger
et al., 2009b). In addition, both compounds were inhibiting
MALT1 activity and selectively inducing apoptosis and thereby
reducing growth of ABC-DLBCL in a preclinical DLBCL xeno-Cantransplantation model. Thus, cellular and in vivo data underscore
the effectiveness of PD as pharmacologic MALT1 inhibitors
and suggest their potential clinical application for ABC-DLBCL
therapy.
MALT1 is the only human paracaspase with very distinct prop-
erties when compared to mammalian caspases (Hachmann
et al., 2012), revealing that specific inhibitors are clearly prom-
ising drug candidates for selective inactivation of the MALT1
oncogenic activity. Selectivity is critical, because impairment of
apoptosis through caspase inhibition would certainly trigger
adverse effects detrimental for lymphoma therapy. Indeed, all
PD tested displayed a high preference for MALT1 and did not
impair the initiator caspase 8 and the executioner caspase 3.
Congruently, mepazine and thioridazine were able to induce
apoptotic cell death in MALT1-dependent ABC-DLBCL.
Michaelis-Menten kinetics and wash-out experiments re-
vealed that mepazine does not directly affect substrate binding
to the catalytic center of MALT1 in a competitive manner, but
rather acts as a noncompetitive and reversible inhibitor. Because
all PD inhibit activity of a catalytically activeMALT1 fragment that
spans the paracaspase and C-terminal Ig3 domain to a similar
extent as the full length protein, they apparently exert allosteric
effects within the active paracaspase domain. The recent eluci-
dation of the crystal structure of theMALT1 paracaspase and Ig3
domains in its free form and bound to the tetrapeptide inhibitor
indicates that substrate binding causes a substantial structural
reorganization to achieve an active protease (Wiesmann et al.,
2012; Yu et al., 2011). Mepazine and thioridazine inhibit constitu-
tive activity of recombinant MALT1, suggesting that PD bind
within the paracaspase-Ig3 region of MALT1 and thereby
possibly counteract the structural rearrangement required to
maintain the active confirmation. Also inside the cells, PD act
directly on the MALT1 paracaspase, as indicated by impaired
cleavage of the substrate RelB. Furthermore, the inhibitory effect
on MALT1 is also evident from the inhibition of MALT1 activity in
in vitro protease assays after IP of cellular MALT1. Thus, in T cells
PD are apparently maintaining MALT1 in an inactive conforma-
tion that is resistant to activation by upstreampathways. Further-
more, the inhibition of constitutiveMALT1 activity in ABC-DLBCL
cells even after IP purification suggests that in the ABC-DLBCL
cells PD are in fact forcing the active MALT1 protease into an
inactive conformation. Mepazine and thioridazine are most likely
causing cellular MALT1 to adopt a structure reminiscent to the
inactive enzyme prior to stimulation. In fact, these results on
cellular MALT1 inhibition are compatible with the noncompeti-
tive, allosteric mode of inhibition that PD exert on recombinant
MALT1. Taken together, our recombinant and cellular data
underscore the efficacy and selectivity of PD as small molecule
MALT1 inhibitors.
In cells, the strong inhibition of cellular MALT1 activity after
relatively short PD incubation times clearly indicated that the
substances were directly affecting MALT1 protease. Mepazine
was 4- to 6-fold more effective than thioridazine in inhibiting
recombinant MALT1 and it was also more effective in cells, indi-
cating that cellular uptake, compound stability, and cellular
concentration may be in a similar range. Different PD have
been or are still in clinical use, reflecting that the phenothiazine
scaffold seems to be a privileged structure to obtain in vivo
effects. Interestingly, toxicity tests on ABC-DLBCL cellscer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Inc. 833
Figure 6. Mepazine and Thioridazine Inter-
fere with Growth and Induce Apoptosis in
ABC-DLBCL Cell Line OCI-Ly10 In Vivo
(A) Transplantation of OCI-Ly10 or Su-DHL-6 cells
resuspended in matrigel into the flanks of NSG
mice was carried out on day 0. Tumor size was
determined by caliper measurement. Intraperito-
neal administration of solvent, mepazine (400 mg/
day) or thioridazine (300 mg/day) was started 24 hr
after transplantation and given continuously every
24 hr for the entire treatment period. Statistical
analysis was performed using a two-way Anova
test (mean ± SD; n = 3).
(B)Mice were treated as in (A) but administration of
compounds was started on day 12 after xeno-
transplantation when tumors were grown to
75 mm2 (mean ± SD; n = 3).
(C) Thioridazine concentrations were measured in
the serum 0–24 hr after i.p. injection (12 mg/kg) by
HPLC (mean ± SD; n = 3).
(D) Apoptosis was determined on tumor sections
(experiment in A) by TUNEL staining after 22 days
of treatment. Pictures show staining of represen-
tative tumor sections (scale bar 100 mm).
(E) RelB and RelBD were detected in extracts of
OCI-Ly10 tumor specimens by western blotting
22 days after transplantation (experiment in A).
Blots show results from three mice treated with
solvent, mepazine, or thioridazine.
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zine. In fact, differential side effects of PD may synergize with
MALT1 inhibition to exert the toxic effect on ABC-DLBCL cells.
In this context, thioridazine has been reported to inhibit PI3K-
PDK1-AKT signaling in ovarian cancer cells (Choi et al., 2008;
Rho et al., 2011). Constitutive AKT phosphorylation is a common
feature of DLBCL cells, independent of their classification. We
observed some effects of thioridazine on AKT phosphorylation
(data not shown), which may account for an augmentation of
thioridazine toxicity. However, as GCB-DLBCL cells, which
also show constitutive PI3K-AKT signaling (Kloo et al., 2011)
and are resistant to thioridazine, MALT1 inhibition is clearly
the primary cause for the cellular toxicity in this setting. We
recently demonstrated that PI3K-PDK1 contributes to enhanced834 Cancer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Inc.MALT1 activity in the two ABC-DLBCL
cell lines HBL1 and TMD8 that carry
oncogenic mutations in the BCR
signaling adaptor CD79B (Kloo et al.,
2011). Clearly, thioridazine did not only
affect survival of HBL1 and TMD8 cells,
but also was toxic to all MALT1-depen-
dent ABC-DLBCL, again indicating that
its primary target is MALT1. Neverthe-
less, concomitant inhibition of PI3K-AKT
may add to the effects of thioridazine on
MALT1.
The important clinical potential of the
three PD identified and analyzed in this
study stems from the fact that all have
been used formerly in trials or in the clinic
as antipsychotic or sedative drugs. Thisactivity in this setting is thought to be based primarily on their
ability to function as dopamine D2 receptor antagonists (Seeman
et al., 1976). Mepazine, the most effective MALT1 inhibitor, has
been evaluated as an antipsychotic and tranquilizing drug under
the brand name Pacatal in the late 1950s and early 1960s.
Whereas some clinical investigations provided evidence for anti-
psychotic effects, other studies failed to do so (Sarwer-Foner
and Koranyi, 1957; Whittier et al., 1960). Some side effects
were reported after mepazine treatment, including a reduction
of asthma attacks, indicating potential immunosuppressive
activity (Sarwer-Foner and Koranyi, 1957). Thioridazine (brand
name Mellaril/Melleril) is still commercially available, but is
reserved for the treatment of schizophrenic patients who do
not respond to other antipsychotic drugs. Thioridazine is also
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because it exerts toxic effects on different cancer cell lines
(Rho et al., 2011; Zhelev et al., 2004). In addition, thioridazine
is considered as a candidate drug for the treatment of tubercu-
losis or malaria, but the reasons for its antimicrobial and antipar-
asitic actions are currently unknown (van Soolingen et al., 2010;
Weisman et al., 2006). Promazine (brand name Sparine), which
displayed the weakest toxicity for MALT1-dependent ABC-
DLBCL, is still used to treat restless behavior.
Comparative analysis of pharmacokinetic (PK) profiles in
rodents and humans further support the possibility for a potential
off-label clinical use of thioridazine to treat ABC-DLBCL. We
measured thioridazine levels of 170–270 ng/ml in the serum of
NSG mice 1 hr after treatment, which is congruent with previous
single dose PK studies after i.p. injection (10 mg/kg) in rats
(Daniel et al., 1997). The concentrations obtained in rodents
are within the range of peak concentrations reported in humans
(130–650 ng/ml) 1–4 hr after oral uptake of 100 mg thioridazine
(Chakraborty et al., 1989; Shvartsburd et al., 1984). However,
whereas in humans considerable concentrations of thioridazine
are still present even after 1 day, the drug is undetectable in
rodents after 24 hr (see Figure 6C; Daniel et al., 1997). A dose
of 10–12 mg/kg in rodents corresponds to800 mg for an adult.
Given these relatively high doses, PK studies clearly demon-
strate a much faster metabolism of thioridazine in rodents com-
pared to humans. Congruently, in rats 2 weeks of chronic i.p.
injection (10 mg/kg twice daily) led to plasma concentrations
of thioridazine that peaked at 750 ng/ml and declined to
90 ng/ml over 24 hr (Daniel et al., 1997). The recommended
therapeutic range of thioridazine in humans has been set to
steady state levels of 200–2,000 ng/ml in the plasma of patients
treated for psychiatric disorders (Baumann et al., 2004). These
data reveal that the thioridazine levels that are effective in killing
xenografted ABC-DLBCL tumors after i.p. injection in mice
are within the range or even below the therapeutic window
that can be achieved after oral administration of thioridazine in
humans. Thus, the PK profile lends support to a possible clinical
off-label use of PD in ABC-DLBCL therapy.
The identification of mepazine, thioridazine, and promazine as
three small molecule inhibitors of MALT1 opens potential addi-
tional therapeutic uses. The inhibitory action of PD on T cell
activation indicates a potential immunosuppressive effect of
MALT1 inhibition that needs to be further explored, but adverse
effects of PD that have mostly terminated a long-term antipsy-
chotic use are certainly not tolerated for an application as
immunosuppressants. However, a restricted short-term usage
of mepazine or thioridazine for treatment of patients with aggres-
sive lymphoma that depends on MALT1 proteolytic activity and
is resistant to current therapeutic protocols can be envisioned.
The overall 5-year survival rate of 35% for patients with ABC-
DLBCL emphasizes the urgent clinical need for alternative treat-
ment options (Lenz et al., 2008b). The increase in apoptosis as
well as the decrease in tumor growth of the ABC-DLBCL cell
line OCI-Ly10 in response to mepazine or thioridazine treatment
in mice underscores the potency of these drugs. Thioridazine is
still on the market and the xenotransplantation model as well as
PK profile suggests that a daily administration of up to 800 mg,
which is the maximal permitted oral dosage in psychotic
patients, could have beneficial effects in patients with ABC-CanDLBCL. A combinatorial therapy could be possible, because
the reduced expression of prosurvival factors after MALT1
inhibition by PD could sensitize ABC-DLBCL tumor cells for
chemotherapy-induced apoptosis. Besides the differential
ABC- andGCB-DLBCL classification, further diagnosticmarkers
to identify patients with lymphoma who would most likely benefit
from MALT1 inhibition by PD are certainly required. In addition,
effectivity and selectivity of MALT1 inhibition by PD can be opti-
mized by medicinal chemistry programs to yield a more potent
and possibly selective drug for the treatment of MALT lymphoma
or ABC-DLBCL.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
DLBCL cell lines (except OCI-Ly10) were cultured in RPMI 1640 medium
(Invitrogen) supplemented with 20% FCS and 100 U/ml penicillin/strepto-
mycin. OCI-Ly10 was cultured in IMDM (Invitrogen) with 20% human plasma,
penicillin/streptomycin and 50 mM b-mercaptoethanol. Jurkat T cells were
cultured like DLBCL cells with 10% FCS. The isolation of PBMCs from
heparin-treated (1000 U/ml) whole blood was done with Lymphoprep accord-
ing to manufacturer (Axis-shield). Isolation of murine CD4+ T cells was per-
formed with T-cell-specific Dynabeads (Invitrogen) and they were cultured in
Jurkat medium and 50 mM b-mercaptoethanol. Stimulation of Jurkat T cells,
PBMCs, andmouse CD4+ T cells was either initiated by the addition of phorbol
12-myristate 13-acetate (PMA; 200 ng/ml) and ionomycin (I; 300 ng/ml) (both
Calbiochem) or by hCD3/hCD28 and mIgG1/mIgG2a antibodies (BD Biosci-
ences). The use of PBMC from healthy donors in this study was approved
by the Ethics Board of the Medical Faculty of the Ludwig-Maximilians-Univer-
sity Munich, Germany and donors gave informed consent.
Z-VRPR-FMK (Alexis Biochemicals), mepazine acetate (Chembridge), pro-
mazine hydrochloride, thioridazine hydrochloride, promethazine hydrochlo-
ride (all Sigma Aldrich), and all other PD tested (Chembridge or Sigma) were
solved in DMSO. Antibodies used were BCL-XL (Cell Signaling), MALT1
(H300, Santa Cruz), c-FLIP (Alexis Biochemicals), b-Actin (I-19, Santa Cruz),
and RelB (Cell Signaling).
Recombinant and Endogenous Protease Cleavage Assays
Recombinant GSTMALT1 was purified from E. coli and all cleavage assays
were in 384-well microplates format using 200 ng of GSTMALT1 and 50 mM
of the substrate Ac-LRSR-AMC. Cleavage activity was determined by the
increase of AMC fluorescence measured in Synergy 2Microplate Reader (Bio-
tek). Reversible inhibition was determined after coupling of 300 ng GSTMALT1
to glutathione sepharose and subsequent wash out of the compounds.
Cleavage of human caspase 3 (BioVision) and caspase 8 (Cayman Chemical)
was assayed accordingly against Ac-DEVD-AMC as substrate using 50 and
250 pg of protein, respectively. Activity of endogenous MALT1 in the absence
or presence of inhibitors was determined after MALT1 IP as described earlier
(Kloo et al., 2011).
Real-Time RT-PCR and ELISA
Synthesis of cDNA was performed with DNA-free RNA samples (RNeasy Mini
Kit, QIAGEN) by reverse transcription with random hexamers and Superscript
II (Invitrogen) according to the manufacturer’s protocol and real-time PCR was
performed using LC 480 SybrGreen PCR mix on a LC 480 Lightcycler system
(Roche). RNAwas normalized by b-Actin mRNA. Primers are shown in Supple-
mental Experimental Procedures.
Human and murine IL-2 (BenderMed Systems), IL-6, and IL-10 ELISAs
(Immunotools) were performed according to the manufacturer’s protocols.
Gene Expression Profiling
Gene expression profiling was performed for the ABC-DLBCL cell line HBL1
after treatment with DMSO or 20 mMof mepazine for the indicated time points.
RNA extraction using RNeasy Mini Kit (QIAGEN) and analysis of whole-
genome Agilent 4 3 44K gene expression arrays (Agilent Technologies)
was performed following the manufacturer’s protocol. Signals from eithercer Cell 22, 825–837, December 11, 2012 ª2012 Elsevier Inc. 835
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HBL1 cells were compared. We applied a previously developed MALT1 and
NF-kB target gene signature to the gene expression data (Hailfinger et al.,
2009b; Kloo et al., 2011). Genes that were significantly downregulated were
determined by paired t test (p < 0.05).
Viability, MTT, and Apoptosis Assays
Viability of DLBCL cell lines was analyzed with a cell count assay of trypan
blue-stained cells after 4 days and by MTT (3-4,5-dimethylthiazol-2-yl-2,5-
diphenyltetrazoliumbromid) cytotoxicity test after 2 days of inhibitor treat-
ment in comparison to DMSO-treated cells. Reduction of MTT to formazan
was measured at 450 nm with a mQuant microplate spectrophotometer
(Biotek). Apoptosis rates were determined with PE-Annexin V staining of
7AAD cells (BD PharMingen) by FACS (LSRII, BD). Data were analyzed
using FlowJo software (Treestar). TUNEL assay was performed on frozen
5 mm DLBCL tumor tissue sections with the DEAD End colorimetric TUNEL
system kit according to the manufacturer’s protocol (Promega). Tissue
sections were stained with H&E and images were taken on a Zeiss Axioplan
microscope.
Lentiviral Transduction
Constitutively active Flag-IKKb (caIKKb) mutant (SS176, 180EE) and GFPwere
linked by a cotranslational processing site T2A (Hadian et al., 2011) and intro-
duced into pLVTHM plasmid. Infection into HBL1 cells was performed as
described earlier (Wiznerowicz and Trono, 2003). After 1 week in culture,
HBL1 cells were sorted by FACS yielding more than 95% GFP-positive
HBL1 cells. Viability of cells in response to phenothiazine treatment was deter-
mined by counting of trypan blue staining.
In Vivo Tumor Cell Engraftment, Treatment of Mice, and PK
Thioridazine
All experiments were approved by the Bavarian State authorities (file no. 115-
09) according to the legal regulations for animal experimentation. Tumors were
engrafted in 6- to 8-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice by subcutaneous injection of 4 3 106 tumor cells (OCI-Ly10 or Su-
DHL-6) resuspended in matrigel (BD). Both tumors were engrafted simulta-
neously on opposite flanks of individual mice, with three mice for each
treatment group. Intraperitoneal administration of solvent, mepazine, or
thioridazine was started 1 or 12 days after transplantation and given continu-
ously every 24 hr thereafter. We used a daily application dose of 300 mg
thioridazine and 400 mg mepazine per animal (25 g), corresponding to approx-
imately 12 mg/kg and 16 mg/kg, respectively. The tumor size was measured
every other day after visual appearance using a caliper and calculated as
square millimeters (length 3 width). Mice were sacrificed when the SU-DHL-
tumor size was above 250 mm2. Statistical data were analyzed with a two-
way Anova test.
For the pharmacokinetic study of thioridazine, NSG mice were i.p. injected
with a single dose of 300 mg. For each indicated time-point three mice were
treated and blood serum concentrations of thioridazine were determined via
HPLC by standardized diagnostic protocol (MVZ Dortmund).
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